Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

We are pleased to have worked with the Masonic Cancer Center, University of Minnesota to treat the first patient with FT596, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.